I think you may find our ASCO abstracts interesting this year. Especially the one that talks about the time dependent variability of immunoreactivity in patients with melanoma.
Take care,
Svetomir
The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who treat people with cancer.
Svetomir N. Markovic, M.D
Education:
Fellowship – Department of Internal Medicine; Division of Hematology, Department of Oncology
Mayo Graduate School of Medicine
Residency – Internal Medicine
Mayo Graduate School of Medicine
Medical College of Pennsylvania
Fellowship – Part-time Post-doctoral; Microbiology/Immunology, Pharmacology
Medical College of Pennsylvania
Ph.D. – Department of Microbiology/Immunology
Medical College of Pennsylvania
Areas of Research
Melanoma
Cancer Immunology and Immunotherapy Program
Clinical Immunology and Immunotherapeutics
Department of Immunology
Prostate Cancer Program
Translational Immunovirology and Biodefense Program
Academic Affiliations
Clinical & Translational Science Program
Immunology Program
Summary:
Translational immunotherapeutics of cancer focused on malignant melanoma and non-Hodgkin's lymphoma. This work includes development and clinical testing of: cancer vaccines; immune boosting agents; novel agents that reconstitute immunity in patients with cancer; and combination therapy directed at enhancing anti-tumor immune responses.
Yes Now I can say my theory holds water and just coming out in May/June at the ASCO
Meeting.I am trying to get this out to all the clinical Oncologists. So they can incorporate this into there trials. I hope I am not stepping on any Toes.
Jimmy B
No comments:
Post a Comment